NEW YORK (GenomeWeb) – Cynvenio Biosysterms and Color announced an agreement today to offer a combined version of their respective liquid biopsy and hereditary cancer tests.

Using the new offering, clinicians can test breast cancer patients for alterations in the 30 genes on Color's hereditary cancer panel, as well as for somatic cancer mutations in the 27 genes that Cynvenio's ClearID breast cancer test covers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.